Q3 2020

10 November 2020

Dr. Andreas Eckert

CEO

1

Global Player Focused on

Niche Markets for Radioisotopes

ISOTOPE PRODUCTS

(industrial components)

Products

Services

Trade

Disposal

67 MM EUR

53%**

MEDICAL*

Radiation Therapy

Radiopharma

Lab Devices

Engineering

60 MM EUR

47%**

HOLDING

(non-operative)

*Since January 1, 2020, Eckert & Ziegler has consolidated its Radiation Therapy and Radiopharma segments under the new name MEDICAL

**figures without Holding segment

127 MM EUR Revenues in Q3-2020

2

Slides only for illustration - the spoken word shall be binding

>800 Employees (Headcounts)

18 Sites Worldwide

Results Q3-2020

(MM EUR)

Revenues 126,9

Net Income

17,7

4%

11%

46%

39%

EUROPE

AMERICA

ASIA

MIDDLE EAST & AFRICA

3

Slides only for illustration - the spoken word shall be binding

Revenue Growth

01-09/2020 Total Revenues: 126,9 mm EUR

01-09/2019 Total Revenues: 133,2 mm EUR

Lost over last year: -6%

80,0

70,0

EUR

60,0

50,0

MM.In

30,0

40,0

20,0

10,0

-

Isotope Products

Medical

Q3-2019

78,5

54,7

Q3-2020

66,8

60,1

-17% YoY due to

Pharma Growth

Compensates

Corona & Oil Price

4

Corona

incl. discontinued and continued operations

Slides only for illustration - the spoken word shall be binding

Q3 Revenues by Segment 2019/2020

In MM. EUR

-17% YoY,

Corona & Oil

80,0

70,0

60,0

50,0

≈ +30% YoY

40,0

-2,7%

30,0

20,0

10,0

-

Isotope Products

Medical

Medical w/o Pharma

Radiopharma

Holding

Q3-2019

Q3-2020

5

Isotope Products: Revenue Growth Q3-2020, in mm EUR

90

80

- 10,6

70

60

- 1,1

5078,5

66,8

40

30

20

Revenues Q3-2019

Organic Growth

Exchange Rate Effects

Revenues Q3-2020

6

Slides only for illustration - the spoken word shall be binding

Medical: Revenue

Growth Q3-2020, in mm EUR

70

60

+ 0,1

+ 5,3

50

40

30

20

+ 54,7

+ 60,1

10

Revenues Q3-2019

Organic Growth

Exchange Rate Effects

Revenues Q3-2020

7

Slides only for illustration - the spoken word shall be binding

Net Income - Distribution and Growth

Q3-2020

8

Slides only for illustration - the spoken word shall be binding

Net Income Growth

01-09/2020 Total Net Income: 17,7 mm EUR

01-09/2019 Total Net Income: 18,3 mm EUR

Lost over last year: -3,2%

14,0

12,0

10,0

EUR

8,0

MM.

6,0

In

4,0

2,0

0,0

Isotope Products

Medical

Q3-2019

8,5

11,0

Q3-2020

4,9

13,7

9

Slides only for illustration - the spoken word shall be binding

Net Income Growth all Segments in Q3-2020, in mm EUR

20,0

18,0

- 3,6

+ 0,3

16,0

+ 2,7

14,0

12,0

10,0

18,3

17,7

8,0

6,0

4,0

2,0

0,0

Net income Q3-2019

Isotope Products

Medical

Holding

Net income Q3-2020

10

Slides only for illustration - the spoken word shall be binding

Isotope Products: Net Income

Growth Q3-2020, in mm EUR

9

8

7

6

-3,2

5

+ 8,5

+ 1,8

4

-1,0

3

+ 4,9

2

1

0

Net income Q3-2019

Organic Growth

Exchange Rate Effects

Tax/Interest/Minorities

Net income Q3-2020

11

Slides only for illustration - the spoken word shall be binding

Medical: Net Income Growth

Q3-2020, in mm EUR

18,0

16,0

+ 0,6

14,0

+ 3,0

-1,1

12,0

+ 1,7

10,0

8,0

6,0

4,0

2,0

0,0

+ 14,0

+ 11,0

Net income Q3-2019

Organic Growth

Pipeline and One-Off

Exchange Rate Effects

Tax/Interest/Minorities

Net income Q3-2020

12

Slides only for illustration - the spoken word shall be binding

Cashflow and Balance Sheet

Q3-2020

13

Slides only for illustration - the spoken word shall be binding

Balance Sheet

as of 30/09/2020, in mm EUR

Cash/Stocks

76

Equity

147

Receivables

30

Minority Interests

1

Inventory

33

IFRS 16 Leasing

19

Intangible Assets

68

Accruals/Provisions

61

Fixed Assets

40

Other Short Term Payables

46

Others

35

Other Long Term Payables

8

Total Assets

282

Total Liabilities & Equities

282

  • Cash at hand of 75 mm EUR + Financial Assets/ Stocks of 1 mm EUR
  • Debt Free
  • Equity Ratio 52% (+ 2% over Dec. 2019)

14

Slides only for illustration - the spoken word shall be binding

Net Liquidity

Q3-2020, in mm EUR

+10 mm EUR

Share Buy-Back

80

80

70

70

60

60

EUR

50

50

MM.In

40

40

30

30

20

20

10

10

0

0

2014

2015

2016

2017

2018

2019

Q3-2020

Zahlungsmittel

22

31

37

58

54

79

75

Darlehen

19

16

12

2

0

0

0

Nettoliquidität

3

15

25

56

54

79

75

Folie nur zur Illustration - es gilt das gesprochene Wort

15

Cashflow

Q3-2020, in mm EUR

EBITDA: 34,8 mm. EUR

100,0

90,0

-9,3

17,0

80,0

-11,0

-0,3

70,0

60,0

78,9

74,9

50,0

40,0

30,0

Liquidity 31.12.19 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Liquidity 30.09.20

* Only Cash at hand without Stocks

16

Slides only for illustration - the spoken word shall be binding

Stock and Dividend

in EUR/Stock

Share-split 1:3 effective since 4 August 2020

50

1,7

40

1,5

1,3

30

1,1

1,7

20

0,9

1,2

10

0,7

0,8

0,6

0,6

0,7

0,6

0,5

0

2014

2015

2016

2017

2018

2019

2020

Dividend in EUR/Share

EUR/Aktie

17

Slides only for illustration - the spoken word shall be binding

Corona Update

Expectations for 2020

Folie nur zur Illustration - es gilt das gesprochene Wort

18

Key Elements of

Guidance 1.0/ 2020 (EBIT)

in mm EUR

19

Slides only for illustration -the spoken word shall be binding

Q1-Actuals Confirm

Original Guidance 1.0

Guidance

Reality

How are we doing?

20

Slides only for illustration - the spoken word shall be binding

HY Results Suggest

Net Income of ≥ 21 mm EUR

Elements of Guidance 2.0

Equivalent of

  • Euro/ share pre-split
    1 Euro/ share post-split

21

Slides only for illustration - the spoken word shall be binding

Key Items Remain on Track

  • Corona seems to have hit bottom
  • Oil price effects seem to have hit bottom
  • No negative effects seen in 2020 for radiopharmaceutical business
  • Lutetium:
    • commercial production started in March 2020
    • High degree of purity/ technology confirmed
    • Pharmaceutical manufacturing license expected early 2021
  • JV in China with TCL Healthcare on HDR moves ahead:
    • Focus is the secondary market of 6.000 to 7.000 clinics
    • JV necessary due to protectionist procurement policies
    • http://www.tcl-healthcare.com.cn/xwdt/show_4.html
  • Set-upof Y-90production lines in Chengdu and Boston progresses according to schedule
  • Strategic pipeline
    • 6 mm USD competitive NIH-NIAID contract awarded for radiation protection pill

Guidance/ short term

Medium term

Strategic

22

Slides only for illustration - the spoken word shall be binding

Expansion Strategy

Gallium-68/ Theranostics

Additional Isotopes (e.g. Lu-177)

EZAG today

Treatment

Diagnosis

Additional indications

23

Slides only for illustration - the spoken word shall be binding

Expansion Strategy

Yttrium-90/ Radioembolisation

Geographic Expansion

Boston(US) site

ROW including

Chengdu(PRC)

China

site

EZAG

todayEurope

SIRTEX Europe

Customer Base

24

Slides only for illustration - the spoken word shall be binding

Short/ Medium Term Goals for

Radiopharma Ingredients

Building Worldwide Supply Chains / Global Network

Status as of March 2020

Lutetium-177

  • Validated technology
  • Value chain has been completed
  • Five reactors qualified thereof two non-European sites
  • First deliveries to customers

Status as of March 2020 Yttrium-90

  • New production site in Boston initiated
  • Production site in Chengdu Chengdu on schedule
  • Numerous alliances in the pipeline

Financial Calendar / IR Contact

10 Nov 2020 Quarterly Report III/2020

17 Nov 2020 German Equity Forum

31 March 2021 Annual Financial Statements 2020

(subject to changes)

ISINDE0005659700

Reuters EUZ.DE

IR Contact

Eckert & Ziegler AG

Karolin Riehle

Investor Relations & PR

Robert-Rössle-Str. 10

D-13125 Berlin

Tel. +49 30 94 10 84-138 Fax +49 30 94 10 84-112 karolin.riehle@ezag.de www.ezag.de

26

Folie nur zur Illustration - es gilt das gesprochene Wort

Thank you!

27

Folie nur zur Illustration - es gilt das gesprochene Wort

Attachments

  • Original document
  • Permalink

Disclaimer

Eckert & Ziegler AG published this content on 12 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 November 2020 11:34:06 UTC